

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

**Cancer Treatments Advisory Committee Provisional recommendations
20 March 2026**

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Pertuzumab and trastuzumab for the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, within the context for treatments for malignancy, subject to Special Authority criteria	*Withheld
Pertuzumab and trastuzumab widened access for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer with an ECOG status score 2-3, within the context for treatments for malignancy, subject to Special Authority criteria	Medium priority
Belzutifan for the treatment of tumours associated with Von-Hippel Lindau disease, within the context for treatments for malignancy, subject to Special Authority criteria	Medium priority
Eltrombopag widened access for the first line treatment of severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria	High priority
Eltrombopag widened access for the second-line treatment of relapsed/refractory severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria	High Priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until the full record is available.

[More information about the agenda items considered at the recent Cancer Advisory Committee meeting can be found on the Pharmac website.](#)

Released 29 April 2026